<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428581</url>
  </required_header>
  <id_info>
    <org_study_id>16-010491</org_study_id>
    <nct_id>NCT03428581</nct_id>
  </id_info>
  <brief_title>Preventing Lymphedema in Axillary Lymph Node Dissection</brief_title>
  <official_title>Preventing Lymphedema in Patients Undergoing Axillary Lymph Node Dissection Via Axillary Reverse Mapping and Lympho-venous Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to answer if axillary reverse mapping (ARM) with lympho-venous
      bypass (LVB) in patients undergoing an axillary lymph node dissection reduces the rate and
      severity of post-operative lymphedema of the arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will undergo an axillary lymph node dissection (ALND). Cluster randomization
      will determine which of these subjects will have the ARM with LVB and which subjects will
      have the ALND without this technique. As a baseline, all subjects will have the circumference
      of their arms measured and complete a questionnaire about lymphedema. Performing the
      measurements and answering a questionnaire will be repeated at 6, 12, 24, and 36 months after
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Less than 5% limb volume increase in the study extremity compared to baseline and the control extremity</measure>
    <time_frame>36 months following surgery</time_frame>
    <description>Bilateral Limb volume measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Less frequently reported symptoms of lymphedema in the study extremity compared to baseline and the control extremity</measure>
    <time_frame>36 months following surgery</time_frame>
    <description>Validated patient reported surveys</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>ALND with ARM +/- LVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALND without ARM +/- LVB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axillary Lymph Node Dissection (ALND)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALND with ARM +/- LVB</intervention_name>
    <description>Subjects will undergo removal of the lymph nodes in the underarm or &quot;axilla&quot; area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection.</description>
    <arm_group_label>ALND with ARM +/- LVB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALND</intervention_name>
    <description>Prospective and retrospective subjects undergoing an ALND.</description>
    <arm_group_label>ALND without ARM +/- LVB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients scheduled to undergo an axillary lymph node dissection

          -  Patients who in the surgeon's judgement are at high risk to convert to an axillary
             lymph node dissection based intraoperative findings

          -  English speaking

        Exclusion Criteria

          -  Prior ipsilateral axillary lymph node dissection

          -  Prior ipsilateral axillary radiation

          -  Patients undergoing sentinel lymph node biopsy only or at low risk of converting to an
             axillary lymph node dissection in the surgeon's judgement

          -  Previous treatment for lymphedema of either arm or prescribed prophylactic treatment
             for lymphedema.

          -  Pregnant patients cannot participate in the substudy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Jakub</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Ramaker, R.N.</last_name>
    <phone>507-538-6984</phone>
    <email>ramaker.sheri@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheri Ramaker, R.N.</last_name>
      <phone>507-538-6984</phone>
      <email>ramaker.sheri@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>James Jakub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James W. Jakub</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Axillary</keyword>
  <keyword>Lymph node</keyword>
  <keyword>Dissection</keyword>
  <keyword>Reverse Mapping</keyword>
  <keyword>Lympho-venous Bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

